A carregar...
Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium
AIMS: Rivaroxaban, a direct inhibitor of activated factor X (FXa), is the only new oral anticoagulant approved for secondary prevention after acute coronary syndrome. Our objective was to identify the possible molecular mechanisms of rivaroxaban that contribute to endothelial function. METHODS: Cell...
Na minha lista:
| Publicado no: | Br J Clin Pharmacol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5777430/ https://ncbi.nlm.nih.gov/pubmed/28940408 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13440 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|